Reaction
Vascular Rupture reporting signals
As of the last recalculation, Vascular Rupture appears in 1,536 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED (PRR 16.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Diphenhydramine Hydrochloride Capsule, Liquid Filled | 26 | 16.8 | 16.8 |
| Ado-Trastuzumab Emtansine | 10 | 16.2 | 16.2 |
| Dolutegravir Sodium | 9 | 13.6 | 13.6 |
| Sucralfate Oral | 14 | 13.5 | 13.5 |
| Sucralfate Oral Suspension | 14 | 13.4 | 13.4 |
| Indomethacin | 13 | 13.4 | 13.4 |
| Hydrocortisone Sodium Succinate | 9 | 13.0 | 13.1 |
| Ibrutinib | 63 | 11.0 | 11.0 |
| Amlodipine Besylate And Valsartan | 8 | 9.8 | 9.8 |
| Ranibizumab | 17 | 8.8 | 8.8 |
| Faricimab | 5 | 8.4 | 8.4 |
| Atazanavir | 8 | 7.6 | 7.6 |
| Tocilizumab | 61 | 7.5 | 7.5 |
| Etonogestrel And Ethinyl Estradiol | 12 | 7.4 | 7.4 |
| Ticagrelor | 16 | 6.9 | 6.9 |
| Alpelisib | 4 | 6.2 | 6.2 |
| Pertuzumab | 12 | 6.0 | 6.0 |
| Golimumab | 35 | 5.6 | 5.6 |
| Romosozumab-Aqqg | 4 | 4.0 | 4.0 |